ArticleFrontiers in pharmacology2026
A mechanistic study of bisphenol a exposure on asthma through integrating clinical research, network toxicology, machine learning, and multi-omics.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: BPA exposure is known to be correlated with asthma incidence. This study aimed to investigate the molecular mechanisms underlying bisphenol A (BPA)-induced asthma. Methods: In this study, network toxicology, machine learning, and bioinformatics approaches were integrated with differential expression analysis across multiple datasets. Clinical validation was performed using serum BPA measurement, lung function tests, and quantitative PCR in peripheral blood mononuclear cells. Results: BPA was significantly elevated in the serum of patients with asthma, showing negative correlations with lung function parameters, such as forced expiratory volume in one second (FEV1), the ratio of FEV1 to forced vital capacity (FEV1/FVC), maximal expiratory flow at 75% of FVC (MEF75), and maximal expiratory flow at 25% of FVC (MEF25), while displaying positive correlations with fractional exhaled nitric oxide, eosinophil count, and eosinophil percentage (p < 0.05). We identified 116 potential target genes associated with BPA-induced asthma, with significant enrichment in the JAK-STAT and Chemokine signaling pathways. Using machine learning and Cytoscape analysis, we further narrowed these to 10 core regulatory genes. BPA exhibits strong binding affinity for five target proteins (CCR3, IL2RB, IL2RA, CXCR4, and CCR7). Quantitative PCR in human peripheral blood mononuclear cells confirmed significant upregulation of the expression of corresponding genes (p < 0.05), with partial gene upregulation correlated with serum BPA levels. Discussion: BPA exposure affects lung function and systemic immune-inflammatory responses in asthma, potentially modulating asthma pathogenesis by targeting specific genes and the JAK-STAT signaling pathway. These findings provide preliminary evidence for further exploration of the molecular mechanisms and potential therapeutic targets in BPA-induced asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.